MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE
A pharmacist displays a box of Mounjaro, an injectable tirzepatide drug used to treat type 2 diabetes and manufactured by Lilly, at Rock Canyon Pharmacy in Provo, Utah, on May 29, 2023.
George Frey | Reuters
Patients who took Eli Lillyweight loss medicine tirzepatide lost up to 34 pounds, or 16% of their body weight, on average, the company said results of clinical trials issued on Thursday.
Eli Lilly plans to finalize its application for FDA approval of the drug in the coming weeks, and expects regulatory action later this year. FDA approved tirzepatide for type 2 diabetes last year, but the drug is not approved for weight loss.
The approval would open up “an opportunity for many more people to benefit from tirzepatide,” Eli Lilly CEO David Ricks said on CNBC’s “Squawk Box” on Thursday. He added that the drug sets “a new standard for weight loss and people with diabetes.”
The data comes as companies try to capitalize on increased consumer demand for weight loss treatments. Some experts have criticized the increased use of drugs as a potentially harmful extension of diet culture.
The phase 3 trial followed 938 overweight adults with type 2 diabetes. Patients taking the 10-milligram version of the injection after 72 weeks lost an average of nearly 30 pounds, while those taking 15 milligrams, lost an average of 34 pounds.
Patients in the placebo group who did not take the pill lost an average of seven kilograms.
About 86% of patients in the trial who took tirzepatide lost at least 5% of their body weight, compared with about 30% in the placebo group.
The rate of average weight loss seen in the trial “has not yet been achieved in Phase 3 trials for obesity or overweight and type 2 diabetes,” Jeff Emmick, Eli Lilly’s senior vice president of product development, said in a statement.
Tirzepatid also lowered the levels A1C, which measures the average blood sugar level over the past three months. Higher A1C levels are associated with a higher risk of diabetes complications.
Eli Lilly said it will continue to monitor the results of the trial. The company will present the findings at a medical conference in June and submits the research to a peer-reviewed journal.
Drugs like tirzepatide and rival Novo NordiskOzempic and Wegovy have catapulted into the national spotlight in recent years for their weight loss.”miracles.”
Social media influencers, Hollywood celebrities and even a billionaire tech mogul Elon Musk are supposed to use popular injections to get rid of unwanted weight.
But experts to say drugs can further perpetuate a dangerous diet culture that idealizes weight loss and thinness.
Some patients who stop taking the medication also complain of weight gain that is difficult to control.
Tirzepatide works by mimicking two naturally produced hormones in the gut called GLP-1 and GIP. Hormones signal the brain when a person is full and suppress their appetite.
Ozempic and Wegovy only target GLP-1. Patients who took Ozempic va 2021 clinical trial lost almost 15% of their body weight.
Earlier this month, Eli Lilly registered a new clinical trial which will compare tirzepatide with Wegovy in 700 patients with obesity or overweight and weight-related health problems. The company expects to complete the study in 2025.
.
MY NUMBER 1 RECOMMENDATION TO LOSE WEIGHT: CLICK HERE
Source